<DOC>
<DOCNO>EP-0646009</DOCNO> 
<TEXT>
<INVENTION-TITLE>
USE OF GUANOSINE IN THE MANUFACTURE OF DRUGS FOR THE TREATMENT OF BRAIN DYSFUNCTION
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3152	A61K31519	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction such as chromosomal syndromes causing mental deficiency as in trisomy 21 and Fragile X syndrome, and behavioral disorders occurring in diseases of the central nervous system such as Alzheimer's disease, and hyperactivity, hyperreactivity, anxiety, or psychotic or autistic syndromes.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
PF MEDICAMENT
</APPLICANT-NAME>
<APPLICANT-NAME>
PIERRE FABRE MEDICAMENT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
LEJEUNE JEROME
</INVENTOR-NAME>
<INVENTOR-NAME>
PEETERS MARIE A
</INVENTOR-NAME>
<INVENTOR-NAME>
LEJEUNE, JEROME
</INVENTOR-NAME>
<INVENTOR-NAME>
PEETERS, MARIE A.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of guanosine for the manufacture of drugs for
the treatment of brain dysfunction.
Use according to Claim 1, characterized in that
the said drugs are intended for the treatment of

chromosomal syndromes causing mental deficiency, such as
trisomy 21 and fragile X.
Use according to Claim 1, characterized in that
the said drugs are intended for the treatment of

behavioural disorders occuring in disease of the central
nervous system, such as Alzheimer's disease.
Use according to Claim 1, characterized in that
the said drugs are intended for the treatment of

syndromes of hyperactivity, of hyperreactivity, of
anxiety, or of psychotic or autistic reactions.
</CLAIMS>
</TEXT>
</DOC>
